A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes

Phase 1 Completed 24 enrolled Kallyope Inc.

RandomizedParallel-groupTriple-blindTreatment

Summary

This is a multiple dose study to evaluate the safety, tolerability, PK, and PD of K-757 and K-833 when co-administered in overweight/obese patients with Type 2 diabetes mellitus (T2DM).

Timeline

Start: 2023-03-13
Primary completion: 2023-07-12
Completion: 2023-07-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	K-757	Unknown	—	Oral
Subject	K-833	Unknown	—	Oral

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes

Summary

Timeline

Drugs

Indications